CoChat
Sign Up
Cited by 163Histone Deacetylase Inhibitors ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease

Open access
Yang, Shuang-shuang, Zhang, Rui, Wang, Gang, Zhang, Yong-fang·2017·Translational Neurodegeneration
DOI 10.1186/s40035-017-0089-1PMC PMC5504819
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent studies, inhibitors of histone deacetylase (HDACs) have been found to be a novel promising therapeutic agents for neurological disorders, particularly for AD and other neurodegenerative diseases. Although HDAC inhibitors have the ability to ameliorate cognitive impairment, successful treatments in the classic AD animal model are rarely translated into clinical trials. As for the reduction of unwanted side effects, the development of HDAC inhibitors with increased isoform selectivity or seeking other directions is a key issue that needs to be addressed. The review focused on literatures on epigenetic mechanisms in recent years, especially on histone acetylation in terms of the enhancement of specificity, efficacy and avoiding side effects for treating AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-017-0089-1

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Xu K Dai XL Huang HC Jiang ZF Targeting HDACs: a promising therapy for Alzheimer's disease Oxidative Med Cell Longev 2011 2011 143269 10.1155/2011/143269 PMC3177096 21941604 · DOI
  2. [2]Zuo L Hemmelgarn BT Chuang CC Best TM The role of Oxidative stress-induced epigenetic alterations in Amyloid-beta production in Alzheimer's disease Oxidative Med Cell Longev 2015 2015 604658 10.1155/2015/604658 PMC4620382 26543520 · DOI
  3. [3]Li X Bao X Wang R Neurogenesis-based epigenetic therapeutics for Alzheimer's disease (review) Mol Med Rep 2016 14 2 1043 1053 27314984
  4. [4]Liu RT Zou LB Lu QJ Liquiritigenin inhibits Abeta(25-35)-induced neurotoxicity and secretion of Abeta(1-40) in rat hippocampal neurons Acta Pharmacol Sin 2009 30 7 899 906 10.1038/aps.2009.74 19574995 PMC4006661 · DOI
  5. [5]Fischer A Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? Neuropharmacology 2014 80 95 102 10.1016/j.neuropharm.2014.01.038 24486385 · DOI
  6. [6]Konsoula Z Barile FA Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders J Pharmacol Toxicol Methods 2012 66 3 215 220 10.1016/j.vascn.2012.08.001 22902970 · DOI
  7. [7]Mai A Rotili D Valente S Kazantsev AG Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise Curr Pharm Des 2009 15 34 3940 3957 10.2174/138161209789649349 19751207 · DOI
  8. [8]Song JM Sung YM Nam JH Yoon H Chung A Moffat E Jung M Pak DTS Kim J Hoe HS A Mercaptoacetamide-based class II Histone Deacetylase inhibitor increases Dendritic spine density via RasGRF1/ERK pathway J Alzheimers Dis 2016 51 2 591 604 10.3233/JAD-150717 26890742 · DOI · Paper page
  9. [9]Benito E Urbanke H Ramachandran B Barth J Halder R Awasthi A Jain G Capece V Burkhardt S Navarro-Sala M HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models J Clin Invest 2015 125 9 3572 3584 10.1172/JCI79942 26280576 PMC4588238 · DOI
  10. [10]Graeff J, Tsai L-H: The potential of HDAC inhibitors as cognitive enhancers. In: Annual review of pharmacology and toxicology, Vol 53, 2013. Volume 53, edn. Edited by Insel PA; 2013: 311-330. 23294310
  11. [11]Hahnen E Hauke J Trankle C Eyupoglu IY Wirth B Blumcke I Histone deacetylase inhibitors: possible implications for neurodegenerative disorders Expert Opin Investig Drugs 2008 17 2 169 184 10.1517/13543784.17.2.169 18230051 · DOI
  12. [12]Lockett GA Wilkes F Maleszka R Brain plasticity, memory and neurological disorders: an epigenetic perspective Neuroreport 2010 21 14 909 913 10.1097/WNR.0b013e32833e9288 20717061 · DOI
  13. [13]Kerridge C Belyaev ND Nalivaeva NN Turner AJ The a beta-clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain J Neurochem 2014 130 3 419 431 10.1111/jnc.12680 24528201 · DOI
  14. [14]Zhang ZY Schluesener HJ Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model J Neuropathol Exp Neurol 2013 72 3 178 185 10.1097/NEN.0b013e318283114a 23399896 · DOI
  15. [15]Lu X Wang L Yu CJ Yu DH Yu G Histone acetylation modifiers in the pathogenesis of Alzheimer's disease Front Cell Neurosci 2015 9 3 10.3389/fncel.2015.00226 26136662 PMC4468862 · DOI
  16. [18]Krishna K Behnisch T Sajikumar S Inhibition of Histone Deacetylase 3 restores Amyloid-beta Oligomer-induced plasticity deficit in Hippocampal CA1 pyramidal neurons J Alzheimers Dis 2016 51 3 783 791 10.3233/JAD-150838 26890755 · DOI
  17. [19]Agis-Balboa RC Pavelka Z Kerimoglu C Fischer A Loss of HDAC5 impairs memory function: implications for Alzheimer's disease J Alzheimers Dis 2013 33 1 35 44 22914591
  18. [20]Zhang L Liu C Wu J Tao JJ Sui XL Yao ZG Xu YF Huang L Zhu H Sheng SL Tubastatin a/ACY-1215 improves cognition in Alzheimer's disease transgenic mice J Alzheimer's Dis 2014 41 4 1193 1205 24844691
  19. [21]Cook C Gendron TF Scheffel K Carlomagno Y Dunmore J DeTure M Petrucelli L Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation Hum Mol Genet 2012 21 13 2936 2945 10.1093/hmg/dds125 22492994 PMC3373241 · DOI
  20. [22]Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, Mook-Jung I. HDAC6 inhibitor blocks Amyloid Beta-induced impairment of mitochondrial transport in Hippocampal neurons. PLoS One. 2012:7(8). PMC3425572 22937007
  21. [23]Robers MB Dart ML Woodroofe CC Zimprich CA Kirkland TA Machleidt T Kupcho KR Levin S Hartnett JR Zimmerman K Target engagement and drug residence time can be observed in living cells with BRET Nat Commun 2015 6 10091 10.1038/ncomms10091 26631872 PMC4686764 · DOI
  22. [24]Govindarajan N Rao P Burkhardt S Sananbenesi F Schluter OM Bradke F Lu J Fischer A Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease EMBO Mol Med 2013 5 1 52 63 10.1002/emmm.201201923 23184605 PMC3569653 · DOI
  23. [25]Zhang L Liu C Wu J Tao J-J Sui X-L Yao Z-G Xu Y-F Huang L Zhu H Sheng S-L Tubastatin a/ACY-1215 improves cognition in Alzheimer's disease transgenic mice J Alzheimers Dis 2014 41 4 1193 1205 24844691
  24. [26]Cook C Carlomagno Y Gendron TF Dunmore J Scheffel K Stetler C Davis M Dickson D Jarpe M DeTure M Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance Hum Mol Genet 2014 23 1 104 116 10.1093/hmg/ddt402 23962722 PMC3857946 · DOI
  25. [27]Lehar J Krueger AS Avery W Heilbut AM Johansen LM Price ER Rickles RJ Short GF 3rd Staunton JE Jin X Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat Biotechnol 2009 27 7 659 666 10.1038/nbt.1549 19581876 PMC2708317 · DOI
  26. [28]Zheng H Fridkin M Youdim M From single target to multitarget/network therapeutics in Alzheimer's therapy Pharmaceuticals 2014 7 2 113 135 10.3390/ph7020113 24463342 PMC3942689 · DOI
  27. [30]Kilgore M Miller CA Fass DM Hennig KM Haggarty SJ Sweatt JD Rumbaugh G Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease Neuropsychopharmacology 2010 35 4 870 880 10.1038/npp.2009.197 20010553 PMC3055373 · DOI · Paper page
  28. [31]Xu WS Parmigiani RB Marks PA Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007 26 37 5541 5552 10.1038/sj.onc.1210620 17694093 · DOI · Paper page
  29. [32]Meng J Li Y Camarillo C Yao Y Zhang Y Xu C Jiang L The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity PLoS One 2014 9 1 e85570 10.1371/journal.pone.0085570 24409332 PMC3883700 · DOI
  30. [33]Cuadrado-Tejedor M Oyarzabal J Lucas MP Franco R Garcia-Osta A Epigenetic drugs in Alzheimer's disease Biomol concepts 2013 4 5 433 445 10.1515/bmc-2013-0012 25436752 · DOI
  31. [34]Cuadrado-Tejedor M Garcia-Barroso C Sánchez-Arias JA Rabal O Pérez-González M Mederos S Ugarte A Franco R Segura V Perea G A first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues Hippocampal synaptic impairment in Alzheimer's disease mice Neuropsychopharmacology 2017 42 2 524 539 10.1038/npp.2016.163 27550730 PMC5399234 · DOI
  32. [35]Yao Z-G Liu Y Zhang L Huang L Ma C-M Xu Y-F Zhu H Qin C Co-location of HDAC2 and insulin signaling components in the adult mouse hippocampus Cell Mol Neurobiol 2012 32 8 1337 1342 10.1007/s10571-012-9859-6 22733364 PMC11498477 · DOI
  33. [36]Noh H Seo H Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve grow factor (NGF) regulation Neuroscience 2014 266 255 265 10.1016/j.neuroscience.2014.02.012 24568732 · DOI
  34. [37]Liu H Zhang JJ Li X Yang Y Xie XF Hu K Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion Pharmacol Biochem Behav 2015 135 53 59 10.1016/j.pbb.2015.05.012 26013850 · DOI
  35. [38]Graff J Tsai LH The potential of HDAC inhibitors as cognitive enhancers Annu Rev Pharmacol Toxicol 2013 53 311 330 10.1146/annurev-pharmtox-011112-140216 23294310 · DOI
  36. [39]Zhan P, Wang X, Liu X, Suzuki T. Medicinal chemistry insights into novel HDAC inhibitors: an updated patent review (2012-2016). Recent Pat Anticancer Drug Discov. 2017;12(4):16–34. 27804867

Cited by

Sorted by citations

Authors
Yang, S.-S., Zhang, R., Wang, G., & Zhang, Y.-F.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
Wang, Gang
ORCID
Venue
Translational Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2017-07-10
Volume
6
Issue
1
Pages
19-19
ISSN
2047-9158 (ISSN-L)
DOI
10.1186/s40035-017-0089-1
PMC
PMC5504819
OpenAlex
W2735906958
Cited by
163
References
3
Citations by year
2026: 16 · 2025: 13 · 2024: 27 · 2023: 20 · 2022: 12 · 2021: 24 · 2020: 18 · 2019: 19 · 2018: 13 · 2017: 1
FWCI
1.31
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (81573401)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, histone deacetylase inhibitors, histone acetylation, chromatin remodeling, epigenetics, HDAC isoform selectivity, cognitive impairment, neurodegenerative diseases, adverse drug reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review